Aktis Oncology CMO exercises options and sells 50K shares

Aktis Oncology, Inc. Chief Medical Officer Akos Czibere reported an exercise-and-sell transaction in Common Stock on July 8, 2026.

Accepted by SEC EDGAR 07/10/2026 - 06:10 AM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

Aktis Oncology, Inc. Chief Medical Officer Akos Czibere reported an exercise-and-sell transaction in Common Stock on July 8, 2026. He exercised stock options to acquire 50,000 shares at $4.95 per share, then sold 50,000 shares in multiple open-market sales at weighted average prices around the high-$20s range, leaving no Common Stock held directly and 221,218 stock options outstanding with a $4.95 exercise price expiring on June 30, 2034.

Insider Trade Summary

Exercise and Sale: 50,000 shares ($1.14M approx. pre-tax spread)

Exercise and Sale 5 txns

Insider Czibere Akos

Role Chief Medical Officer

Sold 50,000 shs ($1.39M)

Approx. gross sale proceeds $1.39M

Approx. exercise cost $248K

Approx. pre-tax spread $1.14M

Share of Position Sold 100%

Type	Security	Shares	Price	Value
Exercise	Stock Option (Right to Buy) F4	50,000	$0.00	$0.00
Exercise	Common Stock	50,000	$4.95	$248K
Sale	Common Stock F1	14,800	$27.1273	$401K
Sale	Common Stock F2	30,829	$27.9521	$862K
Sale	Common Stock F3	4,371	$28.7078	$125K

Holdings After Transaction: Stock Option (Right to Buy) — 221,218 contracts (Direct); Common Stock — 0 shares (Direct)

Holdings Before and After: Stock Option (Right to Buy), 271,218 to 221,218 contracts (Direct); Common Stock, 0 to 0 shares (Direct)

Other Insiders: 1 other insider reported open-market sales of this stock in the 30 days up to this filing.

Footnotes (4)

1. F1. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.5200 to $27.5100, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
2. F2. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.5300 to $28.5000, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
3. F3. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.6300 to $28.7400, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
4. F4. 25% of the original number of shares subject to the option vested on July 1, 2025, and 1/48th of the original number of shares subject to the option vested or shall vest in monthly installments thereafter, subject to the Reporting Person's continuous service through each vesting date, inclusive.

Key Figures

Shares sold: 50,000 shares of Common Stock Sale prices (weighted averages): $27.1273, $27.9521, $28.7078 per share Option exercise price: $4.95 per share +5 more

8 metrics

Shares sold 50,000 shares of Common Stock Total open-market sales by Akos Czibere on July 8, 2026

Sale prices (weighted averages) $27.1273, $27.9521, $28.7078 per share Weighted average prices for three tranches of Common Stock sold

Option exercise price $4.95 per share Exercise price for 50,000 stock options converted into Common Stock

Options exercised 50,000 stock options Number of options exercised by Akos Czibere on July 8, 2026

Options held after transaction 221,218 stock options Total stock options remaining after the reported exercise

Option expiration date June 30, 2034 Expiration for the stock option (right to buy) position

Common Stock held after transaction 0 shares Direct Common Stock holdings of Akos Czibere following the sales

Sale price ranges $26.5200–$28.7400 per share Price ranges for individual trades within the weighted average sale prices

Key Terms

weighted average price, Stock Option (Right to Buy), derivative security, vesting, +1 more

5 terms

weighted average price financial

"The price reported is a weighted average price. These shares were sold in multiple transactions..."

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

Stock Option (Right to Buy) financial

""Stock Option (Right to Buy)" listed as the derivative security title for the option position"

derivative security financial

"Exercise or conversion of derivative security described for transaction code "M""

A derivative security is a financial contract whose value comes from the price or performance of something else, such as a stock, bond, commodity, or market index. For investors it acts like an insurance policy or a wager: it can be used to protect against losses, lock in prices, or amplify gains and losses, so it can change a portfolio’s risk and potential return without owning the underlying asset directly.

vesting financial

"shares subject to the option vested or shall vest in monthly installments thereafter"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

exercise or conversion financial

"transaction code description: Exercise or conversion of derivative security"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transactions did Aktis Oncology (AKTS) report for Akos Czibere?

Aktis Oncology’s Chief Medical Officer Akos Czibere exercised 50,000 stock options at $4.95 and sold 50,000 Common Shares in open-market transactions on July 8, 2026, fully offsetting the exercised shares.

How many Aktis Oncology (AKTS) shares did the CMO sell and at what prices?

Akos Czibere sold a total of 50,000 Common Shares in three tranches at weighted average prices of $27.13, $27.95, and $28.71, with individual trade prices ranging between $26.52 and $28.74.

How many Aktis Oncology (AKTS) stock options does the CMO hold after these transactions?

Following the reported transactions, Akos Czibere holds 221,218 stock options with a $4.95 exercise price, each option representing a right to buy one Common Share, and an expiration date of June 30, 2034.

Does the Aktis Oncology (AKTS) CMO still own Common Stock after the July 8, 2026 trades?

After the July 8, 2026 sales, the Form 4 reports that Akos Czibere directly holds 0 shares of Common Stock, while continuing to hold 221,218 stock options as a derivative position.

What type of transaction is code “M” in the Aktis Oncology (AKTS) Form 4?

In this Form 4, transaction code “M” reflects an exercise of a derivative security. Akos Czibere exercised 50,000 stock options at $4.95 per share, converting them into an equal number of Common Shares.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Czibere Akos

(Last) (First) (Middle)

C/O AKTIS ONCOLOGY, INC.

17 DRYDOCK AVENUE, SUITE 17-401

(Street)

BOSTON MASSACHUSETTS 02210

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Aktis Oncology, Inc. [ AKTS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Medical Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/08/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	07/08/2026		M		50,000	A	$4.95	50,000	D
Common Stock	07/08/2026		S		14,800	D	$27.1273(1)	35,200	D
Common Stock	07/08/2026		S		30,829	D	$27.9521(2)	4,371	D
Common Stock	07/08/2026		S		4,371	D	$28.7078(3)	0	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$4.95	07/08/2026		M			50,000	(4)	06/30/2034	Common Stock	50,000	$0	221,218	D

Explanation of Responses:

1. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.5200 to $27.5100, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

2. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.5300 to $28.5000, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

3. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.6300 to $28.7400, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

4. 25% of the original number of shares subject to the option vested on July 1, 2025, and 1/48th of the original number of shares subject to the option vested or shall vest in monthly installments thereafter, subject to the Reporting Person's continuous service through each vesting date, inclusive.

	/s/ Kyle D. Kuvalanka, as Attorney-in-Fact	07/10/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)